| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2016 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Biodefense Divison | Sell | 4,359 | $33.96 | $148,031.64 | -5.4% | |
| Mar 11, 2016 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 45,000 | $3.65 | $164,250.00 | +3.7% | |
| Mar 11, 2016 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Biodefense Divison | Sell | 11,112 | $33.84 | $376,030.08 | -11.1% | |
| Mar 11, 2016 | EBS Emergent Biosolutions Inc. | Sullivan Louis W62 | Director | Sell | 14,879 | $34.03 | $506,332.37 | -34.3% | |
| Mar 11, 2016 | TXMD Therapeuticsmd, Inc. | Collins Cooper C. | Director | Buy | 16,000 | $6.23 | $99,716.80 | +80.0% | |
| Mar 11, 2016 | IRWD Ironwood Pharmaceuticals Inc | Hecht Peter M | Chief Executive Officer | Sell | 120,000 | $10.72 | $1,286,400.00 | -0.8% | |
| Mar 10, 2016 | EBS Emergent Biosolutions Inc. | Sullivan Louis W62 | Director | Sell | 14,820 | $35.34 | $523,738.80 | -34.2% | |
| Mar 9, 2016 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 150,000 | $10.86 | $1,629,000.00 | -28.6% | |
| Mar 7, 2016 | EBS Emergent Biosolutions Inc. | White Marvin L | Director | Sell | 33,134 | $35.42 | $1,173,606.28 | -17.9% | |
| Mar 7, 2016 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 2,200 | $11.11 | $24,442.00 | -16.6% | |
| Mar 2, 2016 | PRGO Perrigo Co Plc | Kochan Sharon | EVP, Gm International | Sell | 1,490 | $125.28 | $186,667.20 | -20.2% | |
| Mar 1, 2016 | ESPR Esperion Therapeutics, Inc. | Omenn Gilbert S | Director | Buy | 5,000 | $15.28 | $76,400.00 | +100.0% | |
| Mar 1, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | President And CEO | Sell | 19,780 | $63.20 | $1,250,027.96 | -0.7% | |
| Feb 25, 2016 | SNOA Sonoma Pharmaceuticals, Inc. | Schutz James J | Chief Executive Officer | Buy | 5,000 | $1.00 | $4,999.50 | +23.9% | |
| Feb 25, 2016 | ANIK Anika Therapeutics, Inc. | Land Raymond J | Director | Sell | 2,695 | $43.62 | $117,555.90 | -16.0% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 152,154 | $8.53 | $1,297,809.00 | -27.6% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Commercial Officer | Sell | 1,600 | $8.50 | $13,600.00 | -5.5% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 2,778 | $8.50 | $23,613.00 | -7.1% | |
| Feb 24, 2016 | PRGO Perrigo Co Plc | Brown Judy L | Executive VP &CFO | Sell | 2,776 | $123.73 | $343,474.48 | -10.0% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Chief Accounting Officer | Sell | 420 | $8.50 | $3,570.00 | -6.2% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | Graney Thomas | Chief Financial Officer | Sell | 563 | $8.50 | $4,785.50 | -9.9% | |
| Feb 24, 2016 | IRWD Ironwood Pharmaceuticals Inc | Owens Edward P | Director | Buy | 10,000 | $8.32 | $83,200.00 | +7.5% | |
| Feb 24, 2016 | ELTP Elite Pharmaceuticals Inc /nv/ | Treppel Jerry | Former Chairman | Sell | 200,456 | $0.32 | $63,231.36 | -1.2% | |
| Feb 19, 2016 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Chief Operating Officer | Sell | 8,000 | $28.09 | $224,720.00 | -100% | |
| Feb 17, 2016 | JNJ Johnson & Johnson | Stoffels Paulus | Chief Scientific Officer | Sell | 125,000 | $102.43 | $12,803,250.00 | -50.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.